BR0011753A - Composições e métodos para aumentar o efluxo de colesterol e elevar o hdl utilizando a proteìna abc1 transportadora do cassete de ligação de atp - Google Patents
Composições e métodos para aumentar o efluxo de colesterol e elevar o hdl utilizando a proteìna abc1 transportadora do cassete de ligação de atpInfo
- Publication number
- BR0011753A BR0011753A BR0011753-6A BR0011753A BR0011753A BR 0011753 A BR0011753 A BR 0011753A BR 0011753 A BR0011753 A BR 0011753A BR 0011753 A BR0011753 A BR 0011753A
- Authority
- BR
- Brazil
- Prior art keywords
- abc1
- methods
- compositions
- relates
- polypeptides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
Abstract
"COMPOSIçõES E MéTODOS PARA AUMENTAR O EFLUXO DE COLESTEROL E ELEVAR O HDL UTILIZANDO A PROTEìNA ABC1 TRANSPORTADORA DO CASSETE DE LIGAçãO DE ATP". A presente invenção refere-se a novos polipetídeos de ABC1 e moléculas de ácido nucléico codificando os mesmos. A invenção também refere-se a vetores recombinantes, células hospedeiras e composições que compreendem polinucleotídeos de ASC1, bem como a métodos para a produção de polipeptídeos de ABC1. A invenção também referre-se a anticorpos que se ligam, especificamente, aos polipeptídeos de ABCI. Além disso, a invenção refere-se a métodos para aumentar o efluxo de colesterol, bem como a métodos para aumentar a expressão e a atividade de ABC1. A presente invenção refere-se, ainda, a métodos para identificar os compostos que modulam a expressão de ABC1 e os métodos para detectar o nível comparativo de polipeptídeos de ABC1 e polinucleotídeos em um paciente mamífero. A presente invenção também proporciona conjuntos e composições adequadas para peneirar os compostos a fim de determinar a expressão de ABC1 que modula a atividade do composto, bem como conjuntos e composições adequadas para determinar se um composto modula o efluxo de colesterol dependente de ABC1.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14026499P | 1999-06-18 | 1999-06-18 | |
US15387299P | 1999-09-14 | 1999-09-14 | |
US16657399P | 1999-11-19 | 1999-11-19 | |
PCT/US2000/016765 WO2000078972A2 (en) | 1999-06-18 | 2000-06-16 | Regulation with binding cassette transporter protein abc1 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0011753A true BR0011753A (pt) | 2002-04-30 |
Family
ID=27385472
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0011753-6A BR0011753A (pt) | 1999-06-18 | 2000-06-16 | Composições e métodos para aumentar o efluxo de colesterol e elevar o hdl utilizando a proteìna abc1 transportadora do cassete de ligação de atp |
BR0011696-3A BR0011696A (pt) | 1999-06-18 | 2000-06-16 | Composições e métodos para aumento do efluxo de colesterol e elevação de hdl usando proteìna abc1 transportadora de cassete de ligação de atp |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0011696-3A BR0011696A (pt) | 1999-06-18 | 2000-06-16 | Composições e métodos para aumento do efluxo de colesterol e elevação de hdl usando proteìna abc1 transportadora de cassete de ligação de atp |
Country Status (19)
Country | Link |
---|---|
EP (2) | EP1218515B1 (pt) |
JP (4) | JP2003508031A (pt) |
KR (2) | KR20020012612A (pt) |
CN (2) | CN1379817A (pt) |
AR (2) | AR024576A1 (pt) |
AT (1) | ATE422545T1 (pt) |
AU (3) | AU5743400A (pt) |
BR (2) | BR0011753A (pt) |
CA (2) | CA2375781A1 (pt) |
DE (1) | DE60041545D1 (pt) |
HK (2) | HK1046427A1 (pt) |
IL (2) | IL147021A0 (pt) |
MX (2) | MXPA01013175A (pt) |
NO (2) | NO20016114L (pt) |
NZ (3) | NZ529785A (pt) |
SG (2) | SG121853A1 (pt) |
TR (2) | TR200200441T2 (pt) |
TW (2) | TWI304737B (pt) |
WO (2) | WO2000078971A2 (pt) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1854880A1 (en) * | 1999-03-15 | 2007-11-14 | University of British Columbia | Methods and reagents for modulating cholesterol levels |
CA2367955C (en) | 1999-03-15 | 2009-05-19 | University Of British Columbia | Abc1 polypeptide and methods and reagents for modulating cholesterol levels |
WO2001003705A1 (en) * | 1999-07-08 | 2001-01-18 | Tularik Inc. | Compositions and methods for raising hdl cholesterol levels |
EP1239848A2 (en) * | 1999-09-01 | 2002-09-18 | University of British Columbia | Compositions and methods for modulating hdl cholesterol and triglyceride levels |
US6555323B2 (en) * | 2000-02-08 | 2003-04-29 | Pfizer Inc. | Assay for ABCA1 |
BR0110541A (pt) | 2000-05-02 | 2003-04-01 | Aventis Pharma Sa | ácido nucleico isolado, vetor recombinante, célula hospedeira, mamìfero transgênico não-humano, método para triar uma substância ou uma molécula, kit para triar, in vitro, uma molécula ou substância candidato, método para triar, in vivo, uma substância ou molécula, kit ou pacote para triar, in vivo, pelo menos uma molécula ou substância candidato, substância que modifica a transcrição de um polinucleotìdeo de interesse, composição farmacêutica, método e kit para detectar um enfraquecimento da transcrição do gene abc1 em um indivìduo, e, kit ou pacote para triar uma molécula ou substância candidato |
EP1203588A1 (en) * | 2000-11-06 | 2002-05-08 | Bayer Ag | Sterol-independent regulation of ABC1 promoter via oncostatinM |
US7033790B2 (en) | 2001-04-03 | 2006-04-25 | Curagen Corporation | Proteins and nucleic acids encoding same |
WO2003004692A2 (en) * | 2001-07-03 | 2003-01-16 | Xenon Genetics, Inc. | Screening processes for agents modulating cholesterol levels |
WO2003033023A1 (fr) * | 2001-10-12 | 2003-04-24 | Grelan Pharmaceutical Co., Ltd. | Medicaments ameliorant l'hypocholesterolemie hdl |
US6924311B2 (en) | 2001-10-17 | 2005-08-02 | X-Ceptor Therapeutics, Inc. | Methods for affecting various diseases utilizing LXR compounds |
ES2367539T3 (es) | 2001-12-21 | 2011-11-04 | X-Ceptor Therapeutics, Inc. | Moduladores heterocíclicos de receptores nucleares. |
US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
AU2002351412B2 (en) | 2001-12-21 | 2010-05-20 | Exelixis Patent Company Llc | Modulators of LXR |
WO2004058717A1 (en) | 2002-12-20 | 2004-07-15 | X-Ceptor Therapeutics, Inc. | Isoquinolinone derivatives and their use as therapeutic agents |
US8466143B2 (en) | 2003-07-23 | 2013-06-18 | Exelixis, Inc. | Azepine derivatives as pharmaceutical agents |
WO2005116057A1 (en) * | 2004-05-27 | 2005-12-08 | Baker Medical Research Institute | Monoclonal antibody against abca1 |
MX363423B (es) | 2005-05-18 | 2019-03-22 | Ablynx Nv | Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor. |
MX2007014564A (es) | 2005-05-20 | 2008-02-07 | Ablynx Nv | Anticuerpos de vhh de dominio unico contra el factor de von willebrand. |
CA2613522A1 (en) | 2005-06-27 | 2007-01-04 | Exelixis, Inc. | Imidazole based lxr modulators |
US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
JP5227803B2 (ja) | 2006-11-24 | 2013-07-03 | ハイクス ラボラトリーズ合同会社 | スピロキノン化合物及び医薬組成物 |
EP2102244A2 (en) | 2006-12-19 | 2009-09-23 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders |
US20100062004A1 (en) | 2006-12-19 | 2010-03-11 | Ablynx N.V. | Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders |
CA2706425A1 (en) | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Method for obtaining polypeptide constructs comprising two or more single domain antibodies |
JP2011525476A (ja) | 2008-03-05 | 2011-09-22 | アブリンクス エン.ヴェー. | 新規の抗原結合二量体複合体、その製造方法及び使用 |
CA2720763A1 (en) | 2008-04-07 | 2009-10-15 | Ablynx Nv | Amino acid sequences directed against the notch pathways and uses thereof |
EP2403873A1 (en) | 2009-03-05 | 2012-01-11 | Ablynx N.V. | Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof |
US20120053229A1 (en) * | 2009-03-31 | 2012-03-01 | The General Hospital Corporation | Regulation of MIR-33 MicroRNAs in the Treatment of Cholesterol-Related Disorders |
AU2010233658B2 (en) | 2009-04-10 | 2013-11-28 | Ablynx Nv | Improved amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of IL-6R related diseases and disorders |
SI2435410T1 (sl) | 2009-05-28 | 2017-06-30 | Bristol-Myers Squibb Company | Lxr modulatorji |
WO2011045079A1 (en) | 2009-10-15 | 2011-04-21 | Intercell Ag | Hepatitis b virus specific human antibodies |
AR083784A1 (es) | 2010-11-08 | 2013-03-20 | Novartis Ag | Polipeptidos de enlace de los receptores de quimiocina |
TW201242953A (en) | 2011-03-25 | 2012-11-01 | Bristol Myers Squibb Co | Imidazole prodrug LXR modulators |
EP2723772A1 (en) | 2011-06-23 | 2014-04-30 | Ablynx N.V. | Immunoglobulin single variable domains directed against ige |
US9328174B2 (en) | 2012-05-09 | 2016-05-03 | Novartis Ag | Chemokine receptor binding polypeptides |
KR20150023729A (ko) | 2012-06-14 | 2015-03-05 | 암브룩스, 인코포레이티드 | 핵 수용체 리간드 폴리펩티드에 접합된 항-psma 항체 |
US9101745B2 (en) * | 2013-03-14 | 2015-08-11 | Sonogene Llc | Sonochemical induction of ABCA1 expression and compositions therefor |
JP6442475B2 (ja) | 2013-03-15 | 2018-12-19 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Lxr調節因子 |
WO2014152738A1 (en) | 2013-03-15 | 2014-09-25 | Bristol-Myers Squibb Company | Lxr modulators |
NL1040254C2 (en) | 2013-05-17 | 2014-11-24 | Ablynx Nv | Stable formulations of immunoglobulin single variable domains and uses thereof. |
GB201315136D0 (en) * | 2013-08-23 | 2013-10-09 | Univ Glasgow | Cholesterol modulation |
NL2013661B1 (en) | 2014-10-21 | 2016-10-05 | Ablynx Nv | KV1.3 Binding immunoglobulins. |
TN2018000180A1 (en) | 2015-11-27 | 2019-10-04 | Ablynx Nv | Polypeptides inhibiting cd40l |
US11098113B2 (en) | 2016-09-15 | 2021-08-24 | Vib Vzw | Immunoglobulin single variable domains directed against macrophage migration inhibitory factor |
BR112019010061A2 (pt) | 2016-11-16 | 2019-08-13 | Ablynx Nv | polipeptídeos de recrutamento de células t capazes de se ligarem ao cd123 e tcr alfa/beta |
CA3064318A1 (en) | 2017-06-02 | 2018-12-06 | Merck Patent Gmbh | Polypeptides binding adamts5, mmp13 and aggrecan |
SG10202113337YA (en) | 2017-06-02 | 2021-12-30 | Ablynx Nv | Aggrecan binding immunoglobulins |
AU2018277343A1 (en) | 2017-06-02 | 2020-01-02 | Ablynx N.V. | Adamts binding immunoglobulins |
EP3630178A1 (en) | 2017-06-02 | 2020-04-08 | Merck Patent GmbH | Mmp13 binding immunoglobulins |
CN115433733A (zh) | 2021-06-04 | 2022-12-06 | 生物岛实验室 | 环状RNA Circ-ACE2翻译的多肽及其应用 |
CN114369162B (zh) | 2021-12-28 | 2023-05-30 | 合肥天港免疫药物有限公司 | 抗体及其应用 |
WO2024023271A1 (en) | 2022-07-27 | 2024-02-01 | Ablynx Nv | Polypeptides binding to a specific epitope of the neonatal fc receptor |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0110541A (pt) * | 2000-05-02 | 2003-04-01 | Aventis Pharma Sa | ácido nucleico isolado, vetor recombinante, célula hospedeira, mamìfero transgênico não-humano, método para triar uma substância ou uma molécula, kit para triar, in vitro, uma molécula ou substância candidato, método para triar, in vivo, uma substância ou molécula, kit ou pacote para triar, in vivo, pelo menos uma molécula ou substância candidato, substância que modifica a transcrição de um polinucleotìdeo de interesse, composição farmacêutica, método e kit para detectar um enfraquecimento da transcrição do gene abc1 em um indivìduo, e, kit ou pacote para triar uma molécula ou substância candidato |
-
2000
- 2000-06-16 KR KR1020017016286A patent/KR20020012612A/ko not_active Application Discontinuation
- 2000-06-16 AR ARP000103013A patent/AR024576A1/es unknown
- 2000-06-16 MX MXPA01013175A patent/MXPA01013175A/es active IP Right Grant
- 2000-06-16 NZ NZ529785A patent/NZ529785A/en unknown
- 2000-06-16 EP EP00942914A patent/EP1218515B1/en not_active Expired - Lifetime
- 2000-06-16 IL IL14702100A patent/IL147021A0/xx unknown
- 2000-06-16 CA CA002375781A patent/CA2375781A1/en not_active Abandoned
- 2000-06-16 EP EP00942867A patent/EP1190065A2/en not_active Withdrawn
- 2000-06-16 AT AT00942914T patent/ATE422545T1/de not_active IP Right Cessation
- 2000-06-16 WO PCT/US2000/016591 patent/WO2000078971A2/en not_active Application Discontinuation
- 2000-06-16 BR BR0011753-6A patent/BR0011753A/pt not_active Application Discontinuation
- 2000-06-16 JP JP2001515880A patent/JP2003508031A/ja active Pending
- 2000-06-16 KR KR10-2001-7016284A patent/KR100476519B1/ko not_active IP Right Cessation
- 2000-06-16 CA CA002375787A patent/CA2375787C/en not_active Expired - Fee Related
- 2000-06-16 TR TR2002/00441T patent/TR200200441T2/xx unknown
- 2000-06-16 WO PCT/US2000/016765 patent/WO2000078972A2/en not_active Application Discontinuation
- 2000-06-16 SG SG200307656A patent/SG121853A1/en unknown
- 2000-06-16 DE DE60041545T patent/DE60041545D1/de not_active Expired - Fee Related
- 2000-06-16 AU AU57434/00A patent/AU5743400A/en not_active Abandoned
- 2000-06-16 NZ NZ516061A patent/NZ516061A/en unknown
- 2000-06-16 JP JP2001515881A patent/JP2003506097A/ja active Pending
- 2000-06-16 TR TR2002/00440T patent/TR200200440T2/xx unknown
- 2000-06-16 AU AU57467/00A patent/AU777461B2/en not_active Ceased
- 2000-06-16 CN CN00809163A patent/CN1379817A/zh active Pending
- 2000-06-16 BR BR0011696-3A patent/BR0011696A/pt not_active IP Right Cessation
- 2000-06-16 AR ARP000103012A patent/AR024391A1/es unknown
- 2000-06-16 IL IL14702200A patent/IL147022A0/xx unknown
- 2000-06-16 MX MXPA01013174A patent/MXPA01013174A/es unknown
- 2000-06-16 CN CNB008091641A patent/CN100513570C/zh not_active Expired - Fee Related
- 2000-06-16 NZ NZ531401A patent/NZ531401A/en unknown
- 2000-06-16 SG SG200307655A patent/SG121852A1/en unknown
- 2000-08-25 TW TW095113205A patent/TWI304737B/zh active
- 2000-08-25 TW TW089111924A patent/TWI259205B/zh not_active IP Right Cessation
-
2001
- 2001-12-14 NO NO20016114A patent/NO20016114L/no unknown
- 2001-12-14 NO NO20016121A patent/NO20016121L/no not_active Application Discontinuation
-
2002
- 2002-09-26 HK HK02107131.3A patent/HK1046427A1/zh unknown
- 2002-11-13 HK HK02108234.7A patent/HK1046708A1/zh unknown
-
2004
- 2004-11-04 JP JP2004320358A patent/JP4277956B2/ja not_active Expired - Fee Related
-
2005
- 2005-01-14 AU AU2005200171A patent/AU2005200171A1/en not_active Abandoned
- 2005-10-26 JP JP2005311515A patent/JP2006137750A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0011753A (pt) | Composições e métodos para aumentar o efluxo de colesterol e elevar o hdl utilizando a proteìna abc1 transportadora do cassete de ligação de atp | |
Claverol et al. | Mapping and structural dissection of human 20 S proteasome using proteomic approaches | |
Hall et al. | Regulatory domains of erythrocyte ankyrin. | |
Boulanger et al. | Characterization of adenovirus protein IX | |
Rossie et al. | Identification of an intracellular domain of the sodium channel having multiple cAMP-dependent phosphorylation sites. | |
Siegenthaler et al. | A heterocomplex formed by the calcium-binding proteins MRP8 (S100A8) and MRP14 (S100A9) binds unsaturated fatty acids with high affinity | |
Gibson | Polyoma virus proteins: a description of the structural proteins of the virion based on polyacrylamide gel electrophoresis and peptide analysis | |
Brennan et al. | The utility of N, N-biotinyl glutathione disulfide in the study of protein S-glutathiolation | |
Alper et al. | Hormonal control of protein phosphorylation in turkey erythrocytes. Phosphorylation by cAMP-dependent and Ca2+-dependent protein kinases of distinct sites in goblin, a high molecular weight protein of the plasma membrane. | |
Taylor | The in vitro phosphorylation of chromatin by the catalytic subunit of cAMP-dependent protein kinase. | |
Sebastiano et al. | A new deuterated alkylating agent for quantitative proteomics | |
Pierce et al. | ATP-citrate lyase. Structure of a tryptic peptide containing the phosphorylation site directed by glucagon and the cAMP-dependent protein kinase. | |
BRPI9707379C8 (pt) | composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado. | |
Parkhouse | Biosynthesis of J-chain in mouse IgA and IgM | |
Lorand et al. | Dansylcadaverine specific staining for transamidating enzymes | |
Bo et al. | Analyses of differential proteome of human synovial fibroblasts obtained from arthritis | |
Meuller et al. | The membrane topology of proton-pumping Escherichia coli transhydrogenase determined by cysteine labeling | |
Moore et al. | Proliferating cell nuclear antigen/cyclin is an interleukin 2-responsive gene. | |
Lambert et al. | Disulfide crosslinking of Escherichia coli ribosomal proteins with 2-iminothiolane (methyl 4-mercaptobutyrimidate): evidence that the crosslinked protein pairs are formed in the intact ribosomal subunit | |
Murphy et al. | Phosphorylation of purified rat brain Na+ channel reconstituted into phospholipid vesicles by protein kinase C. | |
Zimmer et al. | Stabilization of leukotriene A4 by epithelial fatty acid-binding protein in the rat basophilic leukemia cell | |
Schwanbeck et al. | Cdc2 and Mitogen-activated Protein Kinases Modulate DNA Binding Properties of the Putative Transcriptional RegulatorChironomus High Mobility Group Protein I | |
Kaminska et al. | Ligand‐directed modification of active matrix metalloproteases: activity‐based probes with no photolabile group | |
Trimmer et al. | 36 Phosphorylation of voltage-gated ion channels | |
Sharp et al. | Analysis of human bone alkaline phosphatase isoforms: Comparison of isoelectric focusing and ion-exchange high-performance liquid chromatography |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |